Publications

O’Brien J, Mitchell C, Auerbach S, Doonan L, Ewald J, Everett L, Faranda A,.., Wheeler MW, et al. 2025. Bioinformatic workflows for deriving transcriptomic points of departure: Current status, data gaps, and research priorities. Toxicol Sci 203(2):147-159; doi: 10.1093/toxsci/kfae145. PMID: 39499193.

Rogers JM, Buerger AN, Heintz MM, Palermo CM, Haws LC, Lea IA. 2025. Evaluation of a hypothesized Sertoli cell-based adverse outcome pathway for effects of diisononyl phthalate on the developing testis. Curr Res Toxicol 8:100219; doi: 10.1016/j.crtox.2025.100219. PMID: 40123861.

Lea IA, Buerger AN, Feifarek D, Mihalchik A, Heintz MM, Haws LC, Nyambego H, Goyak K, Palermo C, Borghoff SJ. 2025. Evaluation of the endocrine disrupting potential of Di-isononyl phthalate. Curr Res Toxicol 8:100220; doi: 10.1016/j.crtox.2025.100220. PMID: 40092461. Corrigendum 8:100233; doi: 10.1016/j.crtox.2025.100233; PMID 40529321.

Moyer HL, Vergara L, Stephan C, Sakolish C, Ford LC, Tsai HD, Lin HC, Chiu WA, et al. 2025. Comparative analysis of caco-2 cells and human jejunal and duodenal enteroid-derived cells in gel- and membrane-based barrier models of intestinal permeability. Toxicol Sci 204(2):181-197; doi: 10.1093/toxsci/kfaf011. PMID: 39886939.

Kennedy SB, Heintz MM, Klaren WD, Wikoff DS, Haws LC, Fitch SE. 2025. An integrated ecotoxicological study reliability framework for use in toxicity value development. Environ Tox Chem 44(4):1142-1153; doi: 10.1093/etojnl/vgaf030. PMID: 39873747.

Schaefer HR, Vincent MJ, Burns CJ, Lange SS. 2025. Increasing the utility of epidemiologic studies as key evidence in chemical risk assessment. Toxicol Sci 203(2):166-170; doi: 10.1093/toxsci/kfae134. PMID: 39657235.

Patlewicz G, Williams AJ, Adams M, Shah I, Paul-Friedman K. 2025. A cheminformatics workflow to select representative TSCA chemicals for New Approach Methodology (NAM) screening. Chem Res Toxicol 38(1):129-144; doi: 10.1021/acs.chemrestox.4c00367. PMID: 39655894.

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.

Patterson JA, Motyka J, Salih R, Nordyke RJ, O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6. PMID: 39369117.

Sakolish C, Moyer HL, Tsai HD, Ford LC, Dickey AN, Bajaj P, Villenave R, Hewitt P, et al. 2025. Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform. Drug Metab Dispos 53(1):10001; doi: 10.1124/dmd.124.001488. PMID: 39884810.

Rana Z, Frankenfeld CL, Kennedy E, Bertoldi J, de Jonge E, Cheskin L. 2025. Food sources of energy and nutrients among US college students: The Health Starts Here cohort study. J Am Coll Health 73(1):301-310; doi: 10.1080/07448481.2023.2220397. PMID: 37290009.

Zilber D, Messier KP, House J, Parham F, Auerbach SS, Wheeler MW. 2025. Bayesian gene set benchmark dose estimation for “omic” responses. Bioinformatics 41(1):btaf008; doi: 10.1093/bioinformatics/btaf008. PMID: 39786864.

Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X, Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M, Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227; doi: 10.1080/15459624.2024.2439817. PMID: 39773194.

Wikoff D, Fitch S. 2024. Systematic reviews and evidence-based methods in toxicology. In: Wexler P (ed), Encyclopedia of Toxicology. Elsevier, pp. 875–882.

Firman JW, Boobis A, Hollnagel HM, Kaiser S, Lovell DP, Moretto A, Muller S,…, Patlewicz G. 2024. Evaluating the consistency of judgements derived through both in silico and expert application of the Cramer classification scheme. Food Chem Toxicol 194(Dec):115070; doi: 10.1016/j.fct.2024.115070. PMID: 39447833.

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024, November 2024.

Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I, et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Abstract PCR257, ISPOR EU 2024 (Top 5% Finalist).

Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H, Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1. PMID: 39695574.

Schaefer H. Cadmium–Initiatives to reduce dietary exposure. Society for Risk Analysis Annual Meeting, Austin, TX, 2024.

Oller A, Barroso J, Prieto P, Verougstraete V, Heim K, Henderson R. 2024. Response to letter to editors submitted by PE Rasmussen, P Huntsman, TM Singer, MN Jacobs, and CC Trevithick-Sutton (Aug 2024). Regul Toxicol Pharmacol 154(Dec):105740; doi: 10.1016/j.yrtph.2024.105740. PMID: 39557211.